/

DSGN

Design Therapeutics, Inc.After hours

9.78−1.13 −10.36%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 9.78 0.00%

Open

10.84

Prev close

10.91

Day range

9.4810.98

52-week range

5.2817.25

Volume

727.41K1.23×

Mkt cap

612.05M

P/E ttm

—

Fwd P/E

-6.04

EPS ttm

-1.18

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−43.30%

Price Chart

Yahoo Finance · delayed

DSGNOct 13, 2026O 10.84H 10.98L 9.48C 9.78−1.13 (−10.36%)Vol 727.41K

SMA 5013.69
SMA 20012.09

1Y change +44.89% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DSGN Design Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −18.30%
1 month: −33.15%
3 months: −28.46%
6 months: −22.63%
Year to date: +4.26%
1 year: +50.69%

Valuation & ownership

Market cap: 612.05M
Enterprise value: 478.03M
P/E (ttm): —
Forward P/E: -6.04
PEG ratio: —
Price / book: 3.03
Price / sales (ttm): —
EV / EBITDA: -6.10
EPS (ttm): -1.18
EPS (forward): -1.62
Beta (5y monthly): 1.69
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 62.58M
Float: 36.19M
Short % of float: 14.00%
Short ratio (days): 8.67
Held by insiders: 31.87%
Held by institutions: 78.72%
Avg volume (3m): 591.08K
50-day average: 13.75
200-day average: 12.09
52-week change: +50.69%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 23.5
vs 50-day SMA: −28.56%
vs 200-day SMA: −19.10%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.65%
Realised vol (20d, ann.): 60.9%
From 52-week high: −43.30%
From 52-week low: +85.23%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

21.71

+122.03% implied

Low 20.00Median 21.00High 26.00

Recommendation trend

Now8 / 0 / 0
1m ago7 / 0 / 0

DES

About Design Therapeutics, Inc.

Yahoo Finance profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 55
Headquarters: Carlsbad, CA, United States
Website: designtx.com
Officers: Mr. Pratik Shah Ph.D. Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Dr. Sean Jeffries Ph.D.

SEAS

Seasonality · DSGN

2021–2026 · monthly returns

Strongest month Jul +22.85%Weakest month Jan −24.10%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	8.8	2.3	1.9	27.8	-22.9	38.1	-15.8	23.9	-16.7	-22.2			+4.3%
2025	-21.4	0.2	-20.6	25.9	-23.3	-9.7	14.8	42.9	36.2	-11.0	40.1	-0.1	+52.0%
2024	-10.6	17.3	45.0	-12.7	15.1	-17.3	52.2	-6.9	13.3	-2.6	14.5	2.8	+132.8%
2023	-23.5	-9.9	-18.4	11.8	-12.7	11.9	29.2	-69.5	-4.8	-13.6	17.6	10.4	−74.2%
2022	-41.0	7.4	19.0	-26.1	4.5	12.2	40.1	3.3	-17.5	-6.6	-10.4	-26.7	−52.1%
2021				-12.3	-0.1	-24.1	-22.2	1.6	-6.6	6.7	6.8	27.9	−28.4%

INSD

Insider Activity · DSGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 12, 2025	William Arsani H.Director	Sale at price 5.25 per share.	562.6K	$2.95M
Dec 17, 2024	Prasad DeepaDirector	Sale at price 6.27 per share.	3.8K	$23.86K

13F

Investors Holding DSGN

latest 13F filings of 29 followed managers

Investors holding DSGN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$5.6M	0.01%	387.91K	−5.0%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

DSGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DSGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Design Therapeutics, Inc.

Seasonality · DSGN

Insider Activity · DSGN

Congress Trades · DSGN

Investors Holding DSGN

Investors Holding DSGN

Congress Trades · DSGN

Seasonality · DSGN

Insider Activity · DSGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Design Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News